Lyndon Box, MD
Interventional Cardiology · Caldwell, IDNPI 1174620512
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,767 of the $5,664 with a category attached, or 66.5%. 31 manufacturers reported payments, led by Cardiovascular Systems Inc. at 36.7% of the total. Reporting peaked in 2019 at $2,422 and has fallen 54.4% since, to $1,104 in 2025.
Across 148 payments — averaging $38.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$2K
- Boston Scientific$437
- Novartis$402
- AstraZeneca$396
- Shockwave Medical, Inc$371
- Medtronic$280
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1,88333%
- Food & beverage$3,76767%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 5 | $2,077 |
| Boston Scientific | 15 | $437 |
| Novartis | 25 | $402 |
| AstraZeneca | 18 | $396 |
| Shockwave Medical, Inc | 8 | $371 |
| Medtronic(2 entities) | 8 | $280 |
| Abbott | 8 | $264 |
| Pfizer | 8 | $161 |
| Amgen | 8 | $147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $134 |
| Novo Nordisk | 5 | $133 |
| Edwards Lifesciences | 3 | $107 |
| Philips North America LLC | 2 | $106 |
| Johnson & Johnson | 5 | $79 |
| Cook Medical LLC | 2 | $73 |
| Chiesi USA, Inc. | 1 | $70 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Bard Peripheral Vascular, Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Getinge USA Sales, LLC | 2 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Canon Medical Systems USA, Inc. | 1 | $24 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Recor Medical Inc | 1 | $20 |
| Abiomed | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Bayer | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,664 in reported general payments places this provider in the 65th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 511 | $513,976 |
| EntrestoSacubitril/Valsartan | 152 | $190,784 |
| XareltoRivaroxaban | 125 | $116,227 |
| FarxigaDapagliflozin Propanediol | 118 | $93,868 |
| JardianceEmpagliflozin | 36 | $45,673 |
| Repatha SureclickEvolocumab | 36 | $38,728 |
| BrilintaTicagrelor | 50 | $37,008 |
| Repatha SyringeEvolocumab | 52 | $36,220 |
| Ranolazine ErRanolazine | 35 | $11,739 |
| Metoprolol Succinate | 788 | $8,862 |
| Atorvastatin Calcium | 697 | $7,378 |
| Rosuvastatin Calcium | 338 | $4,310 |
| ClopidogrelClopidogrel Bisulfate | 335 | $3,405 |
| Eplerenone | 53 | $3,288 |
| Carvedilol | 268 | $2,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $161 | $513,976511 claims |
| NovartisEntresto | $402 | $190,784152 claims |
| AstraZenecaFarxiga, Brilinta | $396 | $130,875168 claims |
| Johnson & JohnsonXarelto | $79 | $116,227125 claims |
| Boehringer IngelheimJardiance | $20 | $45,67336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 29 interventional cardiology providers in Idaho.
Other interventional cardiology in Caldwell
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Jeffrey HeslopBoise$17K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
- Robert DuerrBoise$11K
- Andrew MichaelsNampa$7K
- George SamaanNampa$6K
- Ryley McPetersNampa$6K
- Frederick CostelloBoise$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.